Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 8/20 | 0.38 |
| ▸ | CTSL | P07711 | 4/20 | 0.35 |
| ▸ | CTSB | P07858 | 4/20 | 0.35 |
| ▸ | CTSH | P09668 | 2/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | CTSS | P25774 | 1/20 | 0.34 |
| ▸ | LTA4H | P09960 | 1/20 | 0.32 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.32 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.32 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6245315 | 1.00 | CTSK (0.38) | CTSKCTSLCTSBCTSHATM | |
| SCHEMBL9103897 | 0.95 | CTSK (0.33) | CTSKCTSLCTSBCTSHATM | |
| SCHEMBL9102349 | 0.92 | ANPEP (0.33) | CTSKCTSS | |
| SCHEMBL15332671 | 0.85 | — | — | |
| SCHEMBL10656233 | 0.77 | CTSK (0.34) | CTSKCTSLCTSBCTSHCTSS | |
| SCHEMBL1862554 | 0.77 | CTSK (0.39) | CTSKCTSLCTSBCTSHATM | |
| SCHEMBL5065073 | 0.77 | CTSK (0.39) | CTSKCTSLCTSBCTSHATM | |
| SCHEMBL1859132 | 0.76 | CTSK (0.40) | CTSKCTSLCTSBCTSHATM | |
| SCHEMBL1864711 | 0.75 | CTSK (0.36) | CTSKCTSLCTSBCTSHATM | |
| SCHEMBL1865571 | 0.75 | CTSK (0.40) | CTSKCTSLCTSBCTSHATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110105506-A1 | Diaminoalkane aspartic protease inhibitors | VITAE PHARMACEUTICALS, INC. | 2011-05-05 | — | — | US | disclosed |
| US-5106835-A | Hypotensive agents | AMERICAN CYANAMID COMPANY (US) | 1992-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105506-A1 | Diaminoalkane aspartic protease inhibitors | DNPEP, PEPD, ACE | CTSK 31/4885CTSL 82/4885CTSB 64/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.